TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04403230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retreatment of teeth prepared without finish line
Description: Retreatment of teeth treated using biologically oriented preparation technique (BOPT). The sample (149 teeth) was divided into two groups: Seventy four teeth restored with crowns, and 75 teeth supporting fixed partial dentures (FPD).
Study: NCT00838903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Glimepiride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo albiglutide
Description: placebo to match albiglutide

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo albiglutide
Description: placebo to match albiglutide

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo albiglutide
Description: placebo to match albiglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo sitagliptin
Description: placebo to match sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo sitagliptin
Description: placebo to match sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo sitagliptin
Description: placebo to match sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo glimepiride
Description: placebo to match glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo glimepiride
Description: placebo to match glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo glimepiride
Description: placebo to match glimepiride
Study: NCT03313180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Administered twice daily
Study: NCT04595188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulphur amino acids
Description: For the total sulphur amino acid requirement, there are 7 different methionine test levels (without dietary cysteine) ranging from 5 to 40 mg of methionine per kilogram body weight per day.~For the minimum methionine requirement, there are 7 different methionine test levels (with excess dietary cysteine).
Study: NCT01654185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI plus Dimethyldiguanide
Description: AI 1 tablet per day Dimethyldiguanide 0.5 bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: 1 tablet per day
Study: NCT01935609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples counseling
Description: Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
Study: NCT04608396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 taken daily for up to 52 weeks, until relapse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken daily for up to 52 weeks, until relapse.
Study: NCT02625623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab was administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was administered at a dose of 150 mg/m \^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was administered at a dose of 80 mg/m\^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
Study: NCT01689974

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
Study: NCT01545219

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: 8g/day xylo-oligosaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bi-07
Description: 10\^9 CFU B. lactis / day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: 8g/day xylo-oligosaccharide + 10\^9 CFU Bi-07

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8g/day maltodextrin
Study: NCT03825952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MERM - medication event reminder monitor
Description: The MERM will help measure adherence to ART in routine clinical care.
Study: NCT04597762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Description: Cyclosporin eyedrops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Description: Cyclosporin eyedrops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone eyedrops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone eyedrops
Study: NCT03813485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling in upper trapezius
Description: The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the upper trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in upper trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling in lower trapezius
Description: The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the lower trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x 30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in lower trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs
Study: NCT01581983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Mindfulness Meditation
Description: one hour session each week for six weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Mindfulness Meditation
Description: one hour session each week for six weeks
Study: NCT01718210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF medium
Description: incubation of IVF embryos with a specific medium containing GM-CSF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: group of controls treated with a standard IVF medium
Study: NCT01181661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full Group Contingency
Description: This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed Group Contingency
Description: This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
Study: NCT01780727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EGHEM
Description: Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
Study: NCT01536678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
Study: NCT00996528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Philani Intervention Program
Description: Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
Study: NCT02683733

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bio-enhanced Curcumin Soft Gelatin Capsule
Description: Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Aminosalicylic acid
Description: Dosage is as instructed by patient's physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Aminosalicylic acid
Description: Dosage is as instructed by patient's physician
Study: NCT04985214

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on the quality of life
Study: NCT02497391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: administered orally
Study: NCT04570410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary focal resection plus lymph node dissection
Description: Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary focal resection plus lymph node dissection
Description: Primary radical resection plus lymph node dissection was performed in patients with oligometastatic urothelial carcinoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab IV infusion of 200 mg Q3W
Study: NCT04029025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Workflow A
Description: Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Workflow B
Description: 3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Workflow C
Description: Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C)
Study: NCT02625623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC was administered once every 3 weeks.
Study: NCT01182753

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion therapy
Description: Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: proton therapy
Description: Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E.
Study: NCT03337087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Sucrosofate
Description: Given IV
Study: NCT01012869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: everolimus-eluting stent
Description: everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
Study: NCT04604587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. amyloid PET；2. T807 PET
Description: 1. Dynamic PET acquisition for 70 minutes will be acquired after injection of 10±5 mCi 11C-PiB~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807
Study: NCT02571569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1093884
Description: Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1093884
Description: Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1093884
Description: Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
Study: NCT01592643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye Shield
Description: The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
Study: NCT03358472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.
Study: NCT04278053

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inositol-stabilized arginine silicate
Description: Participants were asked to complete the experimental protocol in a 2-hour fasted state. Each participant's brachial artery FMD was assessed twice during each trial, once before supplement ingestion, and again 60 minutes post-ingestion. Male participants were required to wait for a minimum of seven days between trials as a supplement washout period. Female participants reported for supplement trials outside of their follicular phase of the menstrual cycle so that results were not confounded by changes in serum estradiol, which can significantly attenuate flow-mediated dilation. Sixty minutes after supplement consumption, each participant was asked which supplement they thought they had consumed. Participants were also asked whether they experienced any adverse side effects.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inositol-stabilized arginine silicate
Description: Participants were asked to complete the experimental protocol in a 2-hour fasted state. Each participant's brachial artery FMD was assessed twice during each trial, once before supplement ingestion, and again 60 minutes post-ingestion. Male participants were required to wait for a minimum of seven days between trials as a supplement washout period. Female participants reported for supplement trials outside of their follicular phase of the menstrual cycle so that results were not confounded by changes in serum estradiol, which can significantly attenuate flow-mediated dilation. Sixty minutes after supplement consumption, each participant was asked which supplement they thought they had consumed. Participants were also asked whether they experienced any adverse side effects.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: inositol-stabilized arginine silicate
Description: Participants were asked to complete the experimental protocol in a 2-hour fasted state. Each participant's brachial artery FMD was assessed twice during each trial, once before supplement ingestion, and again 60 minutes post-ingestion. Male participants were required to wait for a minimum of seven days between trials as a supplement washout period. Female participants reported for supplement trials outside of their follicular phase of the menstrual cycle so that results were not confounded by changes in serum estradiol, which can significantly attenuate flow-mediated dilation. Sixty minutes after supplement consumption, each participant was asked which supplement they thought they had consumed. Participants were also asked whether they experienced any adverse side effects.
Study: NCT01460329

Intervention type: DEVICE
Intervention: Ultrasonic Cardiac Output Monitor (USCOM).
Description: This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
Study: NCT03578874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV
Study: NCT00615966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diannexin
Description: single dose, 200 µg/kg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diannexin
Description: Single dose, 400 µg/kg IV
Study: NCT01192555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells
Description: 1x10\^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
Study: NCT00490646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Ixabepilone 40 mg/m\^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Docetaxel 100 mg/m\^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.